Defining the Impact of Adjuvant Treatment on the Prognosis of Patients with Inoperable Glioblastoma Undergoing Biopsy-only: Does the Survival Benefit Outweigh the Treatment Effort?

Ronja Löber-Handwerker (ronja.handwerker@gmx.de)
Universitätsklinikum Göttingen: Universitatsmedizin Göttingen

Katja Döring
University Medical Center Göttingen

Christoph Bock
University Medical Center Göttingen

Veit Rohde
University Medical Center Göttingen

Vesna Malinova
University Medical Center Göttingen https://orcid.org/0000-0002-0062-7490

Research Article

Keywords: glioblastoma multiforme, radio-chemotherapy, overall survival, prognostic factors, inoperable glioblastoma

Posted Date: December 30th, 2021

DOI: https://doi.org/10.21203/rs.3.rs-1167838/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Purpose: Patients with inoperable glioblastoma (GBM) usually experience worse prognosis compared to those in whom gross total resection (GTR) is achievable. Considering the treatment duration and its side effects identification of patients with survival benefit from treatment is essential to guarantee the best achievable quality of life. The aim of this study was to evaluate the survival benefit from radiochemotherapy and to identify clinical, molecular, and imaging parameters associated with better outcome in patients with biopsied GBMs.

Methods: Consecutive patients with inoperable GBM, who underwent tumor biopsy at our department from 2005 to 2019 were retrospectively analyzed. All patients had histologically confirmed GBM and were followed up until death. The overall survival (OS) was calculated from date of diagnosis to date of death. Clinical, radiological and molecular predictors of OS were evaluated.

Results: A total of 95 patients with biopsied primary GBM were enrolled in the study. The mean age was 64.3±13.2 years, 56.8 % (54/95) were male and 43.2 % (41/95) female. Mean OS in the entire cohort was 9 months. After stratification for adjuvant treatment a higher median OS was found in the group with adjuvant treatment (7 months, range 2-88) compared to the group without treatment (1 month, range 1-5) Log-rank test, \( p < 0.0001 \).

Conclusion: Patients with inoperable GBM undergoing biopsy indeed experience a very limited OS. Adjuvant treatment is associated with significantly longer OS compared to patients not receiving treatment and should be considered, especially in younger patients with good clinical condition at presentation.

Introduction

Glioblastoma multiforme (GBM) is associated with very limited survival odds requiring a well-balanced management between aggressive treatment to increase the chance of longer survival and the preservation of quality of life. The median overall survival (OS) of GBM patients is 15 months, whereas only 3-5% survive longer than 3 years, who are then already considered long-term survivors. The 10-year survival rate with GBM was estimated to be 0.71% [21]. Besides younger age and good clinical status at diagnosis with independency during every-day life activities, the extent of resection (EOR) is considered as clinically relevant prognostic factor in GBM patients [10]. Since application of 5-aminolevulinic acid (ALA) has significantly improved the rates of gross total resection (GTR) resulting in increased over all (OS)- and progression free survival (PFS), GTR whenever achievable has been pursued as a surgical goal during glioma surgery [18]. However, the risk of postoperative neurological deficits increases with radical tumor resection outlining a delicate line between reaching GTR and avoiding neurological deficits. Especially in eloquently located tumors GTR is often not feasible, even by means of intraoperative neuromonitoring tools [9]. Since neurological deficits are directly associated with worse outcome, the benefit of more radical tumor resection at the expense of neurological deficits is questionable.
Considering the increasing knowledge about GBM growth-patterns as widespread infiltrating tumor at the time of diagnosis, GTR does not seem to be a reasonable surgical goal in patients with multifocal or eloquent GBM [12, 15, 20]. Hence, most neurooncological centers only perform a tumor biopsy for histological confirmation and treatment planning in these patients. The patient population with inoperable GBM is expected to have a very limited survival since they cannot receive maximal available treatment. The actual survival benefit of the radio-chemotherapy in this patient population has not been determined yet. Considering the limited prognosis of these patients on the one side and the strain of adjuvant treatment on the other side, it is of great clinical interest to evaluate the impact of radio-chemotherapy on survival in this specific patient population. The objectives of this study were: 1- to shed light on this heterogeneous patient population with solely biopsied GBM and to elucidate the criteria for inoperability, 2-to assess whether the survival benefit from tumor treatment outweighs the associated burden of radio-chemotherapy regarding the very limited life expectancy, 3-to identify radiological and molecular tumor-specific factors alongside with patient-specific parameters associated with longer OS in patients with biopsied GBM considered inoperable.

Methods

Patient population

We performed a retrospective analysis of a consecutive and homogenous patient cohort from the Stupp-era. GBM was histologically confirmed after performing a biopsy of tumors considered inoperable. The reasons for considering the tumor as inoperable were extracted from medical records and operations reports. To maintain comparable standards of treatment, patients treated at our department in the time interval from 2005 to 2019 were included in the analysis of the study. Patient-specific parameters like age at diagnosis, Karnofsky Performance Status (KPS) at presentation, tumor-specific parameters including tumor location and distribution on imaging, as well as molecular markers such as the presence of MGMT (O-6-methylguanine-DNA methyltransferase) promotor methylation and IDH (isocitrate dehydrogenase)-mutation were documented. Additionally, data regarding adjuvant treatment and treatment response as seen on imaging during the follow-up examinations were gathered. Treatment decisions were made after interdisciplinary case discussion by the institutional tumor-board for tumors of the central nervous system. Volumetric analysis of the tumor on initial magnetic resonance imaging (MRI) was performed using the Brainlab software Elements (Brainlab® Munich, Germany).

Outcome parameters

OS was defined as the time in months from diagnosis to the date of death. Data on patients who were lost to follow-up, were censored. The impact of patient-specific, radiological and molecular tumor-specific markers on survival were evaluated. The treatment response on imaging was analysed according to the response assessment in neuro-oncology criteria (RANO), at 3- and 6-months follow-up imaging. PFS was
defined as time from diagnosis to tumor progression on follow-up imaging according to the RANO criteria for tumor progression [24].

**Statistical analysis**

The statistical analyses were performed by means of GraphPad Prism (Version 9, GraphPad Software, San Diego, CA, USA). For the presentation of baseline data, descriptive statistics and frequency, distribution analysis was done. Continuous variables are depicted as means ± standard deviation (SD), categorical variables as frequencies or percentages. To analyze the difference of continuous variables and categorical data, t- and Chi-square tests were applied respectively. By performing univariate and multivariate linear regression models we analysed the effects of patient-/tumor characteristics on OS. Statistical significance was set as $p < 0.05$. Overall survival rates were calculated by Kaplan Meier method applying a Log-rank test.

**Results**

**Patient characteristics**

A total of 518 patients with newly diagnosed GBM were treated at our department between 2005 and 2019 (15 years), of whom 95 patients (18.3%) received a tumor biopsy without subsequent resection and were eligible for inclusion into further analysis of this study. Mean age was 64.3±13.2 (range 29 to 88) years, 56.8% (54/95) were male and 43.2% (41/95) were female. The median KPS at admission was 70% (range 40-100). Baseline characteristics are depicted in Table 1. The mean age of patients who received adjuvant treatment was significantly lower compared to the patient group without tumor treatment, while the other baseline characteristics were not significantly different.

**Tumor characteristics**

The decision-making criteria whether a tumor was considered inoperable were based on its localization and distribution on initial imaging. Main reasons for a biopsy-only approach were expected neurological deficits by performing GTR. For example, in tumors involving eloquent brain structure or the corpus callosum (bilateral infiltration=butterfly GBM), basal ganglia, brain stem or primary motor cortex, GTR was not reasonably achievable, hence, biopsy-only was performed. Multifocal tumor growth was another common criterium for biopsy-only instead of a resection of all tumor loci. Examples of different localizations and distributions on initial imaging are given in Fig1.

Tumor volume was calculated in 80/95 (84.2%) patients. The initial imaging of 15 patients between 2005 and 2007 was not available digitally, impeding volumetric analysis. Mean initial tumor volume was 28.2 ± 21.2ml, median 23.5ml (range 5–100ml). In 9.5% (9/95) tumors demonstrated multifocal/-local tumor growth, 23.2% (22/95) involved the corpus callosum, and 45.3% (43/95) had a contact to the ventricle
system (Table 1). MGMT promoter methylation was found in 34.4% of the patient population. An IDH-mutation was detected in 6.7% of all patients (Table 1). There were no statistically significant differences regarding tumor characteristics between the two patient groups (Table 1).

### Table 1

Characteristics of A patients with biopsied glioblastoma; B biopsied tumor within out studied patient cohort

| Variable                        | All (n=95) | Tumor therapy (n=63) | No therapy (n=12) | p-value |
|---------------------------------|-----------|----------------------|-------------------|---------|
| **A Baseline patient characteristics** |           |                      |                   |         |
| Age in years                    | Mean (SD) | 64.3 (13.2)          | 61.9 (11.8)       | 73.9 (9.5) | 0.001** |
|                                 | Median (range) | 65 (29-88)           | 64 (30-83)        | 75.5 (56-84) |         |
| Sex                             | Male      | 56.8 %                | 63.5 %            | 41.7 %   | 0.16    |
|                                 | Female    | 43.2 %                | 36.5 %            | 58.3 %   |         |
| KPS %                           | Mean (SD) | 72.9 (14)             | 73.7 (11.9)       | 69.2 (22.3) | 0.65    |
|                                 | Median (range) | 70 (40-100)           | 70 (50-100)       | 70 (40-100) |         |
| **B Tumor characteristics**     |           |                      |                   |         |
| Tumor volume                    | Mean (SD) | 28.3 (20.8)           | 26.3 (20.8)       | 37.8 (20) | 0.12    |
|                                 | Median (range) | 21.5 (5-97)           | 18 (5-97)         | 30 (20-68) |         |
| Tumor location                  | Corpus callosum | 54.1 %                | 51.8 %            | 80 %     | 0.10    |
|                                 | Basal ganglia | 31.1 %                | 33.9 %            | 20 %     | 0.12    |
|                                 | Motor cortex | 18 %                  | 19.6 %            | 0 %      | 0.28    |
|                                 | Multifocal  | 16.4 %                | 17.9 %            | 0 %      | 0.30    |
|                                 | Ventricular contact | 91.7 %               | 90.9 %            | 100 %    | 0.48    |
| Molecular markers                | MGMT methylation | 34.4 %               | 33.3 %            | 50 %     | 0.64    |
|                                 | IDH mutation | 6.7 %                 | 7.1 %             | 0 %      | 0.70    |

### Tumor treatment

After histological confirmation of the diagnosis 66.4% (63/95) of all patients received tumor treatment and 12.6% (12/95) of patients had no treatment (four patients [33.3 %] were not able to receive radio-
chemotherapy due to a KPS < 60% and eight patients [66.7%] declined further treatment). In 20 patients (21%) adjuvant treatment was recommended, but no information was available if the treatment was indeed conducted because they were lost to follow-up. Tumor treatment was performed following the Stupp protocol [19] in 84.1% (53/63) of the patients, 34% (18/53) of whom completed the regimen. In 15.9% (10/63) different treatment regimens were conducted (five patients received radiotherapy alone, three had chemotherapy with lomustine [CCNU] and two patients were treated with a lomustine-temozolomide combination according to the CeTeG protocol [[11]])

Treatment response according to the RANO criteria

Follow-up radiological data for evaluation of treatment response was available in 24 patients (25.3%), 15 of whom (62.6%) received adjuvant treatment according to the Stupp protocol, four patients (16.7%) had radiotherapy alone, three (12.5%) received chemotherapy with lomustine, one was treated following the CeTeG protocol (4.1%), and one patient (4.1%) had no treatment. At 6-month follow up, partial radiological response (RANO 2) was found in seven patients (29.2%), four (16.7%) experienced stable disease (RANO 3), and 13 patients (54.1%) showed progression according to the definition of RANO 4. Examples of the different treatment response according to the RANO criteria are presented in Fig2. Additionally, patients following the Stupp-protocol had significantly longer PFS compared to patients without adjuvant treatment (4 months vs. 2 months, Kaplan Meier curves, Log-rank test, p<0.0001).

Survival analysis

Mean OS in the entire patient cohort was 9±12.6 months (median 5.5 months, range 1-88), whereas half of the patients had an OS shorter than 6 months, and only 15.8% lived longer than 12 months. When stratifying for adjuvant treatment, a significantly higher OS was detected in the patient group, who received treatment (mean 10.6±13.5 months, median 7 months, range 2-88) compared to the patient group without treatment (mean 2.2±1.5 months, median 1 months, range 1-5), Kaplan Meier curves, Log-rank test, p<0.0001 (Fig3). Figure 3 demonstrate a comparison of OS with different treatment regimens, showing the longest OS for the group who completed radio-chemotherapy according to Stupp protocol, followed by other treatment protocols including CeTeG or metronomic temozolomide, and radiation-only and the shortest OS in the group without any adjuvant treatment (Log-rank test, p<0.0001). In the correlation analysis, longer OS was associated with younger age (r=-0.3001, p=0.01), presence of IDH-mutation (r=0.7584, p<0.0001), adjuvant treatment (r=0.2392, p=0.04), and completed radio-chemotherapy according to the Stupp protocol (r=0.5795, p<0.0001). Neither the initial tumor volume, nor tumor location, or the presence of methylation did show a correlation with OS in our study population with biopsied GBM (Table 2). In a multivariate analysis including age, IDH-mutation and completed radio-chemotherapy according to the Stupp protocol only the presence of IDH-mutation (p<0.0001) and a
completed radio-chemotherapy according to the Stupp protocol ($p$=0.01) remained significant independent predictors of longer OS (Table 2).

**Table 2**

Analysis of parameters associated with prolonged OS

| Univariate correlation analysis of parameters associated with longer OS |
|---------------------------------------------------------------|
| **Variables** | **Correlation coefficient** | **95% CI** | **R squared** | **$p$-value** |
|----------------|-----------------------------|-------------|---------------|---------------|
| Age            | -0.3001                     | -0.4972 to -0.0735 | 0.09003 | 0.01*          |
| KPS            | 0.008342                    | -0.1512 to 0.3091 | 0.00695 | 0.48           |
| Tumor volume   | -0.03797                    | -0.2956 to 0.2248 | 0.00144 | 0.77           |
| Multifocal tumor | -0.09319                  | -0.3432 to 0.1692 | 0.00868 | 0.48           |
| Tumor within motor cortex | 0.06643               | -0.1952 to 0.3192 | 0.00441 | 0.62           |
| Tumor within basal ganglia | 0.1191               | -0.1436 to 0.3661 | 0.01419 | 0.37           |
| Tumor within corpus callosum | 0.0195            | -0.2400 to 0.2765 | 0.00038 | 0.88           |
| MGMT methylation | 0.1111                 | -0.2662 to 0.4589 | 0.01235 | 0.56           |
| IDH mutation   | 0.7584                     | 0.5316 to 0.8837 | 0.5752 | <0.0001*       |
| Tumor treatment | 0.2392                   | 0.0079 to 0.4461 | 0.05722 | 0.04*          |
| Completed Stupp protocol | 0.5795                | 0.3989 to 0.7169 | 0.3358 | <0.0001*       |

| Multivariate linear regression analysis of parameters independently associated with longer OS |
|---------------------------------------------------------------|
| **Variables** | **Estimate** | **Standard error** | **95% CI** | **$p$-value** |
|----------------|-------------|-------------------|-------------|---------------|
| Age            | -0.06060    | 0.06345           | -0.1922 to 0.0709 | 0.34          |
| IDH mutation   | 20.63       | 4.177             | 11.97 to 29.29 | <0.0001*      |
| Completed Stupp protocol | 5.097    | 1.917             | 1.122 to 9.072 | 0.01*         |
Discussion

The primary objective of this study was to identify factors associated with longer survival in a patient population with newly diagnosed inoperable GBM with or without subsequent tumor-specific treatment after histological diagnosis confirmation by biopsy-only. The focus of the analysis was put on the evaluation of actual survival benefit from tumor treatment in this very specific subgroup in relation to the therapy burden. Hence, our long-term aim is to avoid possibly futile, however straining, therapy in this patient group with very limited survival odds. In 18% of our consecutive GBM patient cohort, the tumor was considered inoperable due to tumor growth patterns affecting key brain structures and therefore not permitting GTR without causing unacceptable neurological deficits. To the best of our knowledge, this is the largest patient series with newly diagnosed inoperable GBM reported in the literature so far. Our study confirmed a very limited OS (one-month median OS) in patients with inoperable GBM without tumor-specific treatment. In contrast to this, the patient cohort with inoperable GBM, who received tumor treatment (radio-chemotherapy) after histological confirmation of the diagnosis by biopsy, exhibited a significantly longer OS, clearly demonstrating a survival benefit from treatment in this patient population. However, the median OS of patients with inoperable GBM was still significantly lower compared to the reported median OS of operable GBM (9 vs. 15 months), highlighting the prognostic role of GTR in GBM patients. The identification of further clinical, radiological and molecular parameters associated with prolonged survival is of great clinical relevance to facilitate targeted treatment in patients with GBM, in whom GTR is not reasonably achievable.

Definition of tumor operability and prognostic role of extent of resection

The criteria applied for defining inoperability are still a matter of discussion, even though a neurosurgical expert consensus concerning this definition exists. Several factors can affect the perception of tumor resectability such as the experience of the neurosurgeon as well as the technical facilities of the institution [8, 14]. In our patient series, tumor localization within eloquent regions and multifocal tumor distribution on initial MRI were the main determining criteria for inoperability. Nevertheless, advances in functional imaging over time might have facilitated a better interpretation of tumor relation to eloquent regions. Furthermore, surgery can not only contribute to neurooncological benefit but can also result in better clinical condition by prevention of threatening neurological deficits. Thus, resection of a large space-occupying mass or resection of a symptomatic lesion to relieve symptoms in a primary multifocal tumor may be discussed individually. A longitudinal study of patient-reported quality of life, GTR was not only associated with higher PFS and OS but also with higher quality of survival [16]. On the other side there is a risk for surgery-related complications including neurological deficits with a subsequent negative impact on patients’ clinical condition. A meticulous weighting up of operative risks and expected benefits after diagnosis is crucial in order to provide the best achievable survival advantage.
from surgical treatment without additional impairment of patients’ performance status. Even though several studies have shown a survival advantage through cytoreductive surgery in GBM patients there is an ongoing controversial discussion regarding the threshold of extent of resection (EOR) ranging from 78% to 100% [14, 17]. While it is a common practice to perform GBM-resection only if GTR seems achievable, some authors hold the opinion that no threshold can be set, below which tumor resection does not extent survival. They point out the need of balancing between clinically futile and clinically worthwhile extent of tumor resections rather than a strict cutoff line [4]. After performing a systematic review of the literature and a meta-analysis Brown et al. reported a low to moderate evidence that GTR substantially improves OS and PFS compared to subtotal resection [4]. Therefore, a trade-off between the expected survival benefit and the quality of life is necessary, since most GBM patients would rather choose better quality of life than longer life with poor quality. The same applies to tumor treatment with radio-chemotherapy. The benefit of tumor treatment in patients with inoperable GBMs has not been determined yet. Radiation and/or chemotherapy with varying regimens have been already evaluated in patient cohorts with unresectable GBMs showing a survival benefit [2, 3]. These reports are in line with our study, where tumor treatment was associated with significantly longer median OS compared to patients, without tumor therapy. However, there are possible confounders that might have impacted this finding: patients receiving radio-chemotherapy were on average younger, which per se positively influences survival. This may have resulted in a natural selection bias in our study due to patients who did not elect to be treated after a diagnosis of GBM. It is possible that these patients in the no-treatment group tended to decompensate rapidly after diagnosis, had a lower KPS upfront, or had other significant comorbidities that influenced their decision. Therefore, patients in the no-treatment group would experience decreased survival time due to their intrinsic worse clinical condition. Nevertheless, multivariate analysis revealed the presence of IDH-mutation and completed radio-chemotherapy according to Stupp protocol as independent prognostic factors, whereas age was no independent predictor of survival. The identification of further tumor-specific factors influencing OS would facilitate better treatment planning and counseling of patients with inoperable tumors.

Tumor-specific predictors of survival in patients with inoperable GBM

Over the last years several radiological and molecular factors were evaluated for their prognostic impact in GBM patients. Different radiological tumor-characteristics including initial tumor volume, growth patterns, contact to glioma stem-cell-zones, ventricle contact and involvement of the corpus callosum were evaluated as prognostic factors in our study. None of the tumor-specific locations correlated directly with OS in our patient cohort. However, the most common tumor location in the no-treatment group in our study involved the CC (80%). As it is known that patients with butterfly GBM might experience severe personality changes this specific location might have influenced the capacity to tolerate adjuvant treatment. The topic of tumor-specific locations is under discussion in the current literature as different tumor locations offer or limit GTR and consequently influence OS. Recently the team around Müller et al.
tried to grasp this topic by introducing the “expected residual tumor volume” (eRV) and the “expected resectability index” (eRI), hereby quantifying treatment decisions, resectability and survival [13]. The authors demonstrated that the higher the (expected) residual tumor volume and the less the (expected) resectability, the shorter the expected OS. However, the authors acknowledged that different tumor locations might result from different molecular subtypes and therefore might have had a different natural course of progression. So far, four clinically relevant GBM subtypes were identified, each with a distinct molecular pattern, response to standard therapy and natural course [22]. Until now, no association between localization and tumor subtype has been determined and therefore, further stratification for tumor subtype and tumor treatment might have been a valuable addition. The presence of IDH-mutation and MGMT promotor methylation are well-established molecular markers associated with a favorable outcome [4, 25]. In our study, only the presence of IDH-mutation was independently associated with longer OS.

**Treatment response in patients with inoperable GBM**

During follow-up of our cohort, we evaluated treatment response according to the RANO criteria [24]. Most patients who underwent tumor biopsy presented with disease progression within 6 months, but the patient group with tumor treatment demonstrated a prolonged PFS. To date, several studies proved a survival benefit for GBM undergoing GTR versus GBM with subtotal resection or biopsy [1, 5–7]. However, the group of patients with biopsied GBM was mostly not stratified for tumor treatment. A study by Balaña et al. from 2007 evaluated the survival of “biopsy-only GBM” and revealed comparable results to our study. Their cohort comprised 34 patients with grade III and IV gliomas and was therefore more heterogenous than our cohort. They also found a significant survival benefit of patients undergoing biopsy followed by radio-chemotherapy treatment compared to those without any further therapy [1]. In both studies about 60-70% of patients received tumor treatment, which is very similar to the finding of our study (66%). Interestingly all treatment regimens led to prolonged OS compared to the patients without further treatment. The reasons why some patients did not receive any tumor treatment were a reduced KPS, death before therapy initiation or due to patients’ or their family’s refusal [1]. While individualized therapy concepts are of increasing importance and advancements are made regarding biomarkers and more sophisticated therapies in GBM, most treatment strategies are still based on KPS, age and MGMT-promotor status. At present, there are multiple studies that attempt to find individualized therapies according to the molecular subtype [23] that hold the potential for future effective GBM therapy.

**Limitations of the study**

There are several limitations due to the retrospective nature of the study, that need to be acknowledged. Due to missing data on molecular markers in the patients biopsied before 2016, our study could not provide a more diverse evaluation of the molecular markers influencing OS. Also, complete radiological data were only available in 24 of 95 patients. Therefore, the results have to be interpreted with caution.
due to the small sample size. Furthermore, no data on quality of life was available, hence, preventing an evaluation of the compromise of quality of life during radio-chemotherapy, which is a relevant issue and represents a limitation of the study.

Conclusion

Patients with inoperable GBM undergoing biopsy indeed experience a very limited OS. Tumor treatment is associated with significantly longer OS compared to patients not receiving treatment and should be considered, especially in younger patients with good clinical condition at presentation. However, it should be kept in mind that despite benefit of tumor treatment the patient population with inoperable GBM still has a very limited median OS of 9 months with a tumor treatment duration of at least 6 months.

Declarations

Funding

The study was not funded.

Conflict of Interest

All authors declare that they have no conflicts of interest.

All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript.

Availability of data

All available data is already presented in the manuscript.

Code availability

Not applicable.

Ethics approval

The study was approved by the local ethics committee of the University Medicine Göttingen (Study identification number 16/12/20). Due to retrospective nature of the study informed consent was deemed not necessary and all the procedures being performed were part of the routine care. All procedures performed in this...
study were in accordance with the ethical standards of institutional and/or national research committee and with the 1964 Helsinki Declaration.

Consent to participate

Due to retrospective nature of the study informed consent was waived.

Consent for publication

Due to retrospective nature of the study informed consent was waived.

Authors’ contributions

Ronja Löber-Handwerker contributed to data acquisition, data analysis and writing of the manuscript, Katja Döring contributed to data acquisition and analysis, Christoph Bock had a conceptual contribution to the work and contributed to data availability, Veit Rohde critically reviewed the manuscript and was responsible for supervision of the work, Vesna Malinova contributed to conception and design of the work, data analysis and interpretation, and critically reviewed the manuscript.

References

1. Balaña C, Capellades J, Teixidor P, Roussos I, Ballester R, Cuello M, Arellano A, Florena R, Rosell R (2007) Clinical course of high-grade glioma patients with a “biopsy-only” surgical approach: a need for individualised treatment. Clin Transl Oncol 9:797–803. doi: 10.1007/s12094-007-0142-0

2. Beauchesne P, Bernier V, Carnin C, Taillardier L, Djabri M, Martin L, Michel X, Maire J-P, Khalil T, Kerr C, Gorlia T, Stupp R, Pedex R (2010) Prolonged survival for patients with newly diagnosed, inoperable glioblastoma with 3-times daily ultrafractionated radiation therapy. Neuro Oncol 12:595–602. doi: 10.1093/neuonc/noq008

3. Brada M, Ashley S, Dawe A, Gonsalves A, Huchet A, Pesce G, Reni M, Saran F, Wharram B, Wilkins M, Wilkins P (2005) Neoadjuvant phase II multicentre study of new agents in patients with malignant glioma after minimal surgery. Report of a cohort of 187 patients treated with temozolomide. Ann Oncol 16:942–949. doi: 10.1093/annonc/mdt183

4. Brown TJ, Brennan MC, Li M, Church EW, Brandmeir NJ, Rakszawski KL, Patel AS, Rizk EB, Suki D, Sawaya R, Glantz M (2016) Association of the Extent of Resection With Survival in Glioblastoma: A Systematic Review and Meta-analysis. JAMA Oncol 2:1460–1469. doi: 10.1001/jamaoncol.2016.1373

5. Byun J, Kim Y-H, Nam SJ, Park JE, Cho YH, Kim HS, Hong SH, Kim JH, Kim SJ, Kim CJ (2019) Comparison of Survival Outcomes Between Partial Resection and Biopsy for Primary Glioblastoma:
A Propensity Score-Matched Study. World Neurosurg 121:e858–e866. doi: 10.1016/j.wneu.2018.09.237

6. Chaichana KL, Garzon-Muvdi T, Parker S, Weingart JD, Olivi A, Bennett R, Brem H, Quiñones-Hinojosa A (2011) Supratentorial glioblastoma multiforme: the role of surgical resection versus biopsy among older patients. Ann Surg Oncol 18:239–245. doi: 10.1245/s10434-010-1242-6

7. Di L, Heath RN, Shah AH, Sanjurjo AD, Eichberg DG, Luther EM, de la Fuente Ml, Komotar RJ, Ivan ME (2020) Resection versus biopsy in the treatment of multifocal glioblastoma: a weighted survival analysis. J Neurooncol 148:155–164. doi: 10.1007/s11060-020-03508-6

8. Ferroli P, Schiariti M, Finocchiaro G, Salmaggi A, Castiglione M, Acerbi F, Tringali G, Farinotti M, Broggi M, Roberto C, Maccagnano E, Broggi G (2013) Operability of glioblastomas: “sins of action” versus “sins of non-action”. Neurol Sci 34:2107–2116. doi: 10.1007/s10072-013-1345-5

9. Gerritsen JKW, Arends L, Klimek M, Dirven CMF, Vincent AJ-PE (2019) Impact of intraoperative stimulation mapping on high-grade glioma surgery outcome: a meta-analysis. Acta Neurochir (Wien) 161:99–107. doi: 10.1007/s00701-018-3732-4

10. Hardesty DA, Sanai N (2012) The value of glioma extent of resection in the modern neurosurgical era. Front Neurol 3:140. doi: 10.3389/fneur.2012.00140

11. Herrlinger U, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Sabel M, Hau P, Kortmann R-D, Krex D, Grauer O, Goldbrunner R, Schnell O, Bähr O, Uhl M, Seidel C, Tabatabai G, Kowalski T, Ringel F, Schmidt-Graf F, Suchorska B, Brehmer S, Weyerbrock A, Renovanz M, Bullinger L, Galldiks N, Vajkoczy P, Misch M, Vatter H, Stuplich M, Schäfer N, Kebir S, Weller J, Schaub C, Stummer W, Tonn J-C, Simon M, Keil VC, Nelles M, Urbach H, Coenen M, Wick W, Weller M, Fimmers R, Schmid M, Hattingen E, Pietsch T, Coch C, Glas M (2019) Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. Lancet 393:678–688. doi: 10.1016/S0140-6736(18)31791-4

12. Krex D, Mohr B, Appelt H, Schackert HK, Schackert G (2003) Genetic analysis of a multifocal glioblastoma multiforme: a suitable tool to gain new aspects in glioma development. Neurosurgery 53:1377–1384. discussion 1384 doi: 10.1227/01.neu.0000093426.29236.86

13. Müller DMJ, Robe PA, Ardon H, Barkhof F, Bello L, Berger MS, Bouwknegt W, den Brink WAV, Nibali MC, Eijgelaar RS, Furtner J, Han Sj, Hervey-Jumper SL, Idema AJS, Kiesel B, Kloet A, Munck JCD, Rossi M, Sciortino T, Vandertop WP, Visser M, Wagemakers M, Widhalm G, Witte MG, Zwinderman AH, Hamer PCDW (2021) Quantifying eloquent locations for glioblastoma surgery using resection probability maps. Journal of Neurosurgery JNS 134:1091–1101. doi: 10.3171/2020.1.JNS193049

14. Orringer D, Lau D, Khatri S, Zamora-Berridi GJ, Zhang K, Wu C, Chaudhary N, Sagher O (2012) Extent of resection in patients with glioblastoma: limiting factors, perception of resectability, and effect on survival. J Neurosurg 117:851–859. doi: 10.3171/2012.8.JNS12234

15. Patil CG, Yi A, Elramsisy A, Hu J, Mukherjee D, Irvin DK, Yu JS, Bannykh SI, Black KL, Nuño M (2012) Prognosis of patients with multifocal glioblastoma: a case-control study. J Neurosurg 117:705–711.
16. Sagberg LM, Solheim O, Jakola AS (2016) Quality of survival the 1st year with glioblastoma: a longitudinal study of patient-reported quality of life. J Neurosurg 124:989–997. doi: 10.3171/2015.4.JNS15194

17. Sanai N, Polley M-Y, McDermott MW, Parsa AT, Berger MS (2011) An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg 115:3–8. doi: 10.3171/2011.2.jns10998

18. Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen H-J (2006) Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 7:392–401. doi: 10.1016/S1470-2045(06)70665-9

19. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996. doi: 10.1056/NEJMoa0508395

20. Syed M, Liermann J, Verma V, Bernhardt D, Bougatf N, Paul A, Rieken S, Debus J, Adeberg S (2018) Survival and recurrence patterns of multifocal glioblastoma after radiation therapy. Cancer Manag Res 10:4229–4235. doi: 10.2147/CMAR.S165956

21. Tykocki T, Eltayeb M (2018) Ten-year survival in glioblastoma. A systematic review. J Clin Neurosci 54:7–13. doi: 10.1016/j.jocn.2018.05.002

22. Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O’Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98–110. doi: 10.1016/j.ccr.2009.12.020

23. Weller M, Stupp R, Hegi M, Wick W (2012) Individualized Targeted Therapy for Glioblastoma: Fact or Fiction? The Cancer Journal 18

24. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963–1972. doi: 10.1200/JCO.2009.26.3541

25. Wykes V, Zisakis A, Irimia M, Ughratdar I, Sawlani V, Watts C (2021) Importance and Evidence of Extent of Resection in Glioblastoma. J Neurol Surg A Cent Eur Neurosurg 82:75–86. doi: 10.1055/s-0040-1701635

**Figures**
Figure 1

Overview of the different tumor localizations in our patient cohort with different growth patterns on initial contrast enhanced MRI: GBM with bilateral infiltration growing as a butterfly GBM involving the corpus callosum (upper left), multifocal GBM with multiple contrast-enhanced tumor areas (upper right), motor cortex GBM involving the precentral gyrus (lower left), and GBM within the basal ganglia (lower right).

Figure 2

Examples of good and poor response to tumor treatment as seen on contrast enhanced MRI and based on the RANO (response assessment in neuro-oncology criteria) criteria, showing varying responses to treatment according to the RANO criteria comparing initial MRI with contrast with radiological response at follow-up at 3 and 6 months after tumor treatment: A: partial radiological response (RANO 2), B: stable disease (RANO 3) and C: disease progression as defined by RANO 4.

Figure 3

A Kaplan-Meier curves showing significantly longer OS in the patient group that received tumor treatment compared to the patient group without tumor treatment (log-rank test, \( p < 0.0001 \)).

B Kaplan-Meier curves showing the longest OS within the group that received R-CH according to the Stupp protocol, followed by other treatment protocols including CeTeG or metronomic temozolomide and RT alone, with the shortest OS in the group without tumor treatment (log-rank test, \( p < 0.0001 \)).